ANTIVERSE
Antiverse is a new type of antibody discovery company accelerating drug development. Its platform exists at the intersection of structural biology, machine learning, and medicine to enable breakthroughs to happen more quickly and cost-effectively. It is dedicated to engineering the future of drug development to change the course of people's lives.
ANTIVERSE
Social Links:
Industry:
Artificial Intelligence (AI) Biotechnology Health Care Life Science Machine Learning
Founded:
2017-04-01
Address:
Cardiff, Cardiff, United Kingdom
Country:
United Kingdom
Website Url:
http://www.antiverse.io
Total Employee:
11+
Status:
Active
Total Funding:
4.26 M GBP
Technology used in webpage:
Font Awesome HSTS U.S. Server Location Ruby On Rails Token Rack Cache Level 3 Communications Varnish 6.x Teamtailor Section.io
Similar Organizations
AccutarBio
AccutarBio employs artificial intelligence to revolutionize drug discovery.
Qureator (Formerly known as Curiochips)
Precision Architecture For Drug Discovery
HEALTH[at]SCALE Technologies
Machine Intelligence for Precision Delivery of Healthcare
Menten AI
Menten AI develops peptide and protein therapeutics using machine learning and quantum computing.
Moebio Barcelona
Moebio educates changemakers to improve the future of health, medicine & biotech.
Pera Labs
Pera Labs develops digiceuticals and AI-powered solutions for fertility.
Pharmacelera
Quantum-Mechanics (QM) and Machine Learning (ML) Drug Discovery
Protai
Protai is an AI-powered drug discovery startup.
Current Advisors List
Current Employees Featured
Founder
Investors List
Innospark Ventures
Innospark Ventures investment in Seed Round - Antiverse
Kadmos Capital
Kadmos Capital investment in Seed Round - Antiverse
Deep Science Ventures
Deep Science Ventures investment in Seed Round - Antiverse
NLS Ventures
NLS Ventures investment in Seed Round - Antiverse
Tensor Ventures
Tensor Ventures investment in Seed Round - Antiverse
AngelHub
AngelHub investment in Seed Round - Antiverse
Development Bank of Wales
Development Bank of Wales investment in Seed Round - Antiverse
Tomorrow Scale
Tomorrow Scale investment in Seed Round - Antiverse
Ed Parkinson
Ed Parkinson investment in Seed Round - Antiverse
SyndicateRoom
SyndicateRoom investment in Seed Round - Antiverse
Newest Events participated
Participated in Accelerate@Babraham Start-ups Competition - 11.07.2018
on 2018-07-11 as contestant
Official Site Inspections
http://www.antiverse.io Semrush global rank: 8.81 M Semrush visits lastest month: 462
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Antiverse"
Antiverse: Designing Antibodies For Challenging Targets
About Antiverse Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against challenging targets, including G-protein coupled receptors and ion channels. Headquartered in Cardiff, UK and with …See details»
Antiverse - Crunchbase Company Profile & Funding
Contact Email [email protected] Antiverse is a new type of antibody discovery company accelerating drug development. Its platform exists at the intersection of structural biology, machine learning, and medicine to enable breakthroughs to …See details»
Antiverse Company Profile 2024: Valuation, Funding
Antiverse has 23 total employees. What industry is Antiverse in? Antiverse’s primary industry is Discovery Tools (Healthcare). Is Antiverse a private or public company? Antiverse is a Private company. What is Antiverse’s current …See details»
Antiverse Raises £3.5M ($4.6M) from i&i biotech fund and other ...
Oct 15, 2024 Luke Bateman, [email protected] . Martin Kovalčík, [email protected], +420 777 472 863. About Antiverse. Antiverse is an artificial intelligence-driven techbio company that …See details»
Nxera Pharma and Antiverse Enter Collaboration To Design Novel …
Nov 5, 2024 The collaboration combines Antiverse’s generative AI antibody design expertise, including its proprietary machine-learning-generated ‘ epitope-specific libraries,’ with Nxera’s …See details»
Antiverse raises funding for therapeutic antibody identification
Mar 1, 2023 Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, today announced the successful identification of functional …See details»
Antiverse raises funding and demonstrates therapeutic …
Cardiff, Wales, UK, 01 March 2023: Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, today announced the successful identification of functional antibody clusters …See details»
Antiverse Raises £3.5M ($4.6M) to Advance Generative AI …
Cardiff, Wales, UK, 15 October 2024: Antiverse, a techbio company designing antibodies for challenging targets, today announced it has added £3.5M ($4.6M) to its seed funding. The …See details»
Antiverse Raises $2 million to Advance AI Antibody Drug …
Apr 5, 2021 “Antiverse has an ambitious team of AI experts and scientists with a vision to transform drug discovery. This is a great example of a world class business taking off in Wales …See details»
Antiverse Raises Funding and Demonstrates Therapeutic Antibody ...
Mar 2, 2023 Peter Pack, antibody engineer and NED at Antiverse, added: “Antiverse’s AI-powered methods to generate nanomolar binders against “difficult” antigens such as GPCRs …See details»
Antiverse Raises $3 Million in Funding - The SaaS News
Mar 2, 2023 Antiverse, a Wales, UK-based biotechnology company developing a computational antibody drug discovery platform, announced that it raised $3 million in funding. The company …See details»
Antiverse Raises Funding and Demonstrates Therapeutic Antibody ...
Mar 2, 2023 Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, today announced the successful identification of functional …See details»
Antiverse Raises Funding and Demonstrates Therapeutic
Mar 2, 2023 CARDIFF, Wales--(BUSINESS WIRE)-- Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, today announced the …See details»
Antiverse And GlobalBio, Inc. Extend Collaboration To Advance …
Oct 16, 2023 Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors …See details»
Antiverse Raises Funding and Demonstrates Therapeutic Antibody ...
Mar 1, 2023 Peter Pack, antibody engineer and NED at Antiverse, added: “Antiverse’s AI-powered methods to generate nanomolar binders against “difficult” antigens such as GPCRs …See details»
Antiverse Raises £1.4 Million ($2 Million USD) to Advance Its AI ...
Mar 16, 2021 CARDIFF, WALES, UK — March 15, 2021 — Antiverse, a biotechnology company developing a computational antibody drug discovery platform, has raised seed funding totalling …See details»
Why We Invested: Antiverse - Innospark Ventures
Jun 14, 2023 Antiverse solves the problem of binding to a small piece of a GPCR with an interesting AI implementation. Rather than trying to bind to the GPCR target using a random …See details»
Nxera Pharma and Antiverse Enter Collaboration To Design
Nov 5, 2024 Murat Tunaboylu, Co-founder and CEO at Antiverse, said: “Around 220 GPCRs with known disease links are undrugged, and antibodies are an essential tool in our mission to …See details»
Antiverse and GlobalBio, Inc. extend collaboration to ... - Substack
Oct 16, 2023 Cardiff, UK and Massachusetts, US, 11 October 2023: Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, and …See details»
Antiverse Ltd.. (10/15/24). "Press Release: Antiverse Raises £3.5M …
Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against challenging targets, including G-protein coupled receptors (GPCRs) and ion channels. …See details»